4.7 Review

Insights into Computational Drug Repurposing for Neurodegenerative Disease

Journal

TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 40, Issue 8, Pages 565-576

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2019.06.003

Keywords

-

Funding

  1. National Institute on Aging (NIA) [1R0AG057683, R01AG060393]
  2. NIA [F31AG058439]

Ask authors/readers for more resources

Computational drug repurposing has the ability to remarkably reduce drug development time and cost in an era where these factors are prohibitively high. Several examples of successful repurposed drugs exist in fields such as oncology, diabetes, leprosy, inflammatory bowel disease, among others, however computational drug repurposing in neurodegenerative disease has presented several unique challenges stemming from the lack of validation methods and difficulty in studying heterogenous diseases of aging. Here, we examine existing approaches to computational drug repurposing, including molecular, clinical, and biophysical methods, and propose data sources and methods to advance computational drug repurposing in neurodegenerative disease using Alzheimer's disease as an example.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available